shares plunged late Monday following a brief halt as the biotech drug developer put two clinical trials on hold after one study participant died. Affimed shares dropped 28% after hours, following an 11% gain to close at $4.63 Monday. The company halted two Phase 1, or early-stage, clinical stage for its cancer treatment AFM11 after one patient died and two others experienced “life-threatening events” in the high-dose group. Phase 1 studies are used to gauge the safety of an experimental drug. The studies were testing the drug in patients with types of non-Hodgkin lymphoma and acute lymphoblastic leukemia.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.